Gabriel N. Hortobagyi, MD, on How Best to Use Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in HR+/HER2− Early Breast Cancer

Posted: Monday, February 26, 2024

Gabriel N. Hortobagyi, MD, of The University of Texas MD Anderson Cancer Center, discusses the latest findings from the NATALEE trial, which confirmed the efficacy of ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) over a NSAI alone in patients with hormone receptor–positive, HER2-negative early breast cancer. He explores the questions of dosing and calculating the risk/benefit ratio of this regimen.

---